The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand

References

• Nesdale A, Baker M, Gane E et al. Hepatitis C infection in New Zealand: estimating the current and future prevalence and impact. Porirua: Institute of Environmental Science and Research, 2000.
   Google Scholar
• Chetwynd J, Brunton C, Blank M et al. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. NZ Med J 1995;108:364–366.
   Google Scholar
• Carter H, Robinson G, Hanlon C et al. Prevalence of hepatitis B and C infection in a methadone clinic popula- tion: implications for hepatitis B vaccination. NZ Med J 2001; 114:324–6.
   Google Scholar
• Law MG. Modelling the hepatitis C virus epidemic in Australia. J Gastroenterol Hepatol 1999;14:1100–7.
   PubMedGoogle Scholar
• Seef LB. Natural history of hepatitis C. Hepatology 1997;26(Suppl. 1): 21S-8.
   Google Scholar
• National Institutes of Health Consensus Development Conference Panel. Statement Management of Hepatitis C. Hepatology 1997;26(Suppl.1): 2S–10.
   Google Scholar
• Wong JB, McQuillan GM, McHutchison et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562–9.
   Google Scholar
• Brown K, Crofts N. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users. Aust NZ J Public Health 1998;22:384–8.
   PubMedGoogle Scholar
• Shiell A. Economic analyses for hepatitis C: a review of Australia’s response. In: Lowe D, Cotton R, eds. Hepatitis C: a review of Australia’s response, ch. 7. Canberra: Department of Health and Aged Care, Commonwealth of Australia, 1999.
   Google Scholar
• Blakely T, Salmond C, Tobias M. Hepatitis B virus carrier prevalence in New Zealand: population estimates using the 1987 police and customs personnel survey. NZ Med J 1998;111:142–4.
   PubMedGoogle Scholar
• Gane E. Chronic hepatitis B virus infection in South Auckland. NZ Med J 1998;111:120–3.
   PubMedGoogle Scholar
• Bar-Shany S, Green MS, Slepon R et al. Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepatitis 1995;2:139–44.
   Google Scholar
• Kemp R, Miller J, Lungley S et al. Injecting behaviours and prevalence of hepatitis B,C and D markers in New Zealand injecting drug user populations. NZ Med J 1998;111:50–3.
   Google Scholar
• Dore GM, Walker JD, Paice JR et al. Methadone maintenance treatment: outcomes from the Otago metha- done Programme. NZ Med J 1999;112:442–5.
   PubMedGoogle Scholar
• Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863–73.
   PubMed Web of Science ®Google Scholar
• Wong JB, Koff RS, Tine F et al. Cost-effectiveness of interferon alpha 2b treatment for hepatitis B e antigen- positive chronic hepatitis B. Ann Int Med 1995;122:664–75.
   Google Scholar
• Younossi ZM, Singer ME, McHutchison JG et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318–23.
   Google Scholar
• Wong JB, Poynard T, Ling MH et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastro- enterol 2000;95:1524–30.
   PubMedGoogle Scholar
• Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000;108:366–73.
   PubMedGoogle Scholar
• Dolan M. The hepatitis C handbook. London: Catalyst Press, 1997.
   Google Scholar
• Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463–6.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG et al. Estimating progres- sion to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809–16.
   PubMed Web of Science ®Google Scholar
• Dukes PD, Robinson GM, Robinson BJ. Mortality of intravenous drug users: attenders of the Wellington drug clinic, 1972-89. Drug Alcohol Rev 1992;11:197–201.
   PubMedGoogle Scholar
• Ministry of Health. Mortality and demographic data 1996. This publication uses the Australian version of ICD 9- CMA-II. Wellington: Ministry of Health, 1997.
   Google Scholar
• Durie M. Mauri ora: the dynamics of Maori Health. Oxford: Oxford University Press, 2001.
   Google Scholar
• Shiell A, Briggs A, Farrell GC. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268–72.
   PubMed Web of Science ®Google Scholar
• Sellman JD, Hannifin J, Deering D, Borren P. Delivery of treatment for people with opioid dependence in New Zealand: options and recommendations. A commissioned paper for the Ministry of Health. New Zealand, 1996.
   Google Scholar
• Crofts N, Wodak A. Gaining control of the hepatitis C virus epidemic in Australia. In: Crofts N, Dore G, Locarnini S, eds. Hepatitis C: an Australian perspective, ch. 22. Melbourne: IP Communications, 2001.
   Google Scholar
• Sellman D, Deering D, Robinson G. Methadone main- tenance treatment: coming of age in New Zealand. NZ Med J 1995;108:128–30.
   PubMedGoogle Scholar
• Gines P, Quinterro E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122–28.
   Google Scholar